{
    "nct_id": "NCT04171037",
    "official_title": "A Pilot Study of FDA Approved Optiflowâ„¢ THRIVE Versus Standard Non-Rebreathers in Patients With Potential High Risk of Airway Obstruction During Total Intravenous Anesthesia (TIVA) While Undergoing Interventional Radiology Procedures",
    "inclusion_criteria": "* Signed consent for the study\n* Patients with an SpO2 greater than or equal to 95% while breathing room air\n* Patients requiring total intravenous anesthesia (TIVA) but not tracheal intubation during the proposed procedure - PLUS, any of the 2 following criteria: Body mass index (BMI) greater than or equal to 32 kg/m^2, or neck circumference greater than or equal to 43 cm in a male and 41 cm in a female, or has been diagnosed with moderate to severe obstructive sleep apnea (OSA) with/without using a continuous positive airway pressure (CPAP) device\n* Full course head and neck radiotherapy less than or equal to 6 months (the peak onset time of acute facial and airway edema)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Significant pulmonary disease requiring supplemental oxygen in daily life (severe pulmonary fibrosis, severe chronic obstructive pulmonary disease, etc.)\n* Significant cardiac disease (including history of myocardial infarction [MI] with concurrent evidence of ischemic myocardial damage at the event, cardiomyopathy with impaired left ventricular ejection fraction to less than 50% or uncompensated congestive heart failure)\n* TIVA is contraindicate or having a proposed procedure without TIVA\n* Endotracheal intubation is required\n* American Society of Anesthesiologists (ASA) physical status classification 5\n* Patients who are non-English speaking\n* Emergency procedures",
    "miscellaneous_criteria": ""
}